Insider buying last 90 days
No open-market insider purchases were filed for IART in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every IART insider filing, plotted on the chart in Gekko.Open IART in Gekko
NASDAQ: IART
Integra LifeSciences (IART) Stock Analysis & Forecast
Oct 12 close
$13.98+0.54 (+4.0%)
Gekko Brief
AI summaryOct 12 closeIntegra LifeSciences this week centered on a $450 million debt refinancing, with the company pricing 9.500% senior secured notes due 2033 on October 9, 2026, a private placement expected to close around October 19, 2026, with proceeds alongside a new credit facility used to refinance existing debt. This follows a cut to its 2026 revenue outlook. Separately, a law firm has announced it is investigating the company on behalf of stockholders, and a comparison piece weighed IART against Precision Optics on valuation and other factors.
IART closed at $13.98, up 4% on the day, with trend mixed as the price sits between its 50-day average of $16.17 and 200-day average of $14.07. Over the past month the stock is down 9.8%, and over three months down 24%, though it remains up 36.5% over six months. The GekkoIndex reads 64.7, placing it in the Accumulation zone, down 8.8 over five days. The gap to Gekko Fair Value of $18.58 stands at -24.8%.
Earnings are due on 21 October 2026 before the open, 9 days away and inside a typical 20-trading-day holding window; the last report showed a reaction of -13.4% despite an EPS beat. No insider, Congress, or unusual options activity in the past 90 days or 30 days respectively is on record. Seasonally, the next 20 trading days have averaged +12.2% over 5 years, rising in 3 of them. Analyst coverage from 7 firms shows 6 hold ratings and 1 sell, with a consensus target of $18.38.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Integra LifeSciences price vs fair value
Close $13.98200-day averageGekko Fair Value $18.58
Integra LifeSciences quick facts
- Market cap
- $1.09B
- P/E ratio
- —
- Forward P/E
- 6
- EPS, TTM
- −$0.09
- Revenue, TTM
- $1.65B
- Profit margin
- -0.4%
- Dividend yield
- —
- Beta
- 1.21
- Volume
- 893,706 avg 1.16M
- 1-year return
- −1.3%
- Typical daily move
- ±6%
- Typical 20-day move
- ±8%
- 50-day average
- $16.17
- 200-day average
- $14.07
- Next earnings
- Oct 21 before open
- Shares outstanding
- 77.77M
Integra LifeSciences swing-trade checklist
Integra LifeSciences scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
- Trendmixed
Averages disagree
Close $13.98 sits between the 50-day ($16.17) and 200-day ($14.07) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
64.7, Accumulation
Reading 64.7 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
24.8% below
Price is 24.8% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 9 days
Reports on Oct 21, 2026, 9 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+12.2% on average
From this point in the calendar, the next 20 trading days averaged +12.2% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Integra LifeSciences stock chart and price history
Integra LifeSciences closed at $13.98 on Oct 12, 2026, −1.3% over the past year, inside a 52-week range of $8.70 to $20.49.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −9.8%
- 3 months
- −24.0%
- 6 months
- +36.5%
- 1 year
- −1.3%
The full IART chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open IART in Gekko
Follow Integra LifeSciences through every session
Put IART on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track IART in GekkoFree for 7 days. No credit card required.
About Integra LifeSciences
Integra LifeSciences designs, makes and distributes surgical implants and instruments used in neurosurgery, limb reconstruction and broader surgical care. The company is known for a large catalog of surgical instrument designs, numbering roughly 40,000, alongside lighting products and equipment used in operating rooms, dental offices, podiatry and veterinary practices.
The business is split into two segments. Codman Specialty Surgical covers neurosurgical and neuro-critical care items such as tissue ablation tools, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, cranial stabilization hardware, surgical headlamps and related software and support services. Tissue Technologies focuses on regenerative products for acute and chronic wounds, along with tissue repair solutions for hernia, nerve and tendon procedures, skin repair, plastic and reconstructive surgery, and bone grafting. Products reach customers through direct sales teams and other channels, serving hospitals, health networks, purchasing organizations, individual clinicians and surgery centers across the United States, Europe, Asia Pacific and other regions.
Integra LifeSciences was founded in 1989 and is based in Princeton, New Jersey. Its shares are listed on the NASDAQ under the ticker IART.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- integralife.com
Integra LifeSciences GekkoIndex: the smart money zone
Integra LifeSciences’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 64.7, in the Accumulation zone, down 8.8 points over five sessions.
64.7Accumulation
Down 8.8 points over five sessions, from the Buying zone.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 83 | 0.0% | −1.7% | ||
| Accumulation (current zone) | 289 | −0.5% | −3.0% | ||
| Neutral | 280 | −0.4% | −0.8% | ||
| Distribution | 25 | −2.3% | +3.8% | ||
| Selling | 5 | Too few readings yet | |||
Average IART share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the IART price, zone by zone.Track IART in Gekko
Is Integra LifeSciences stock overvalued? Gekko Fair Value
Integra LifeSciences trades 24.8% below Gekko Fair Value of $18.58, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Integra LifeSciences shares are worth, recalculated every trading day.
$18.58
Gekko Fair Value, Oct 10, 2026
24.8% Undervalued
At the end of Aug 2026 the price was 16.0% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open IART in Gekko
Integra LifeSciences insider and Congress trading
No open-market insider purchases were filed for Integra LifeSciences, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in IART were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for IART, plotted on the chart in Gekko.Open IART in Gekko
Buybacks
Integra LifeSciences has been buying back its own shares.
- Bought back, quarter ended Dec 31, 2025
- $137K
- As a share of market cap
- 0.01%
From company filings.
Integra LifeSciences earnings: next date and track record
Integra LifeSciences reports on Oct 21, 2026, before the open (9 days away), and beat the EPS estimate in 7 of its last 8 reports.
Next earnings report
Oct 21, 2026
Expected before the open, 9 days away
- EPS estimate
- $0.56
- Revenue estimate
- $415.4M
7 of 8reports beat the EPS estimate
±16.2%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Jul 29, 2026 AI summary
- What they said
- Integra reported Q2 2026 revenue of $419 million (0.8% reported, 0.7% organic) and adjusted EPS of $0.56, a 24% increase vs. prior year and above the high end of guidance driven by operational execution and tariff favorability. Gross margin improved to 61.3% and adjusted EBITDA margin to 18.7%; operating cash flow was $22.8 million and capex $12.3 million. Management reaffirmed full-year organic revenue growth guidance and adjusted EPS guidance, updated reported revenue guidance for FX, and noted they are right-sizing tariff assumptions and expect about $0.10 of tariff exposure for the year. Key strategic items: improved supply reliability, continued recovery of PriMatrix, planned phased SurgiMend relaunch in Q4 2026 (not assumed materially in 2026 guidance; management expects roughly 50% of historical legacy contribution over multiple quarters), DuraSorb PMA on a longer timeline, and MediHoney targeted to return in 2027. Management reiterated $25–30 million of 2026 transformation savings (with an incremental $10–15 million annualized benefit in 2027) and expects remediation and transformation costs to decline. Leadership changes in commercial organization aim to drive enterprise contracting and cross-divisional sales. Risks discussed include ENT reimbursement pressures, competitive dynamics in wound reconstruction (Micromatrix powder entrants), tariff and FX variability, higher interest expense from a planned refinancing, and regulatory timing/inspections tied to PMAs and warning-letter remediation.
- Guidance
- Reaffirmed full-year organic revenue growth outlook of 0.8% to 3.3% and reaffirmed adjusted EPS guidance (unchanged). Updated reported revenue range to reflect foreign exchange. Company expects roughly $0.10 of tariff exposure for 2026 (tariff assumptions right-sized); did not assume meaningful SurgiMend or MediHoney contribution in 2026. Q3 expected to be roughly flat vs Q2, with a Q4 step-up of about $25 million. Transformation savings of $25–30 million in 2026 (with $10–15 million annualized in 2027). No 2027 financial guidance provided on the call.
- Risks flagged
- Regulatory and timing risk related to FDA pre-approval inspections and warning-letter remediation; reimbursement pressure in ENT (sinus balloon reimbursement headwinds); competitive pressure in wound reconstruction (new powder entrants affecting MicroMatrix); tariff exposure and foreign exchange variability; increased interest expense due to planned refinancing; supply reliability still improving but remains a factor; execution risk on product relaunches (SurgiMend, PriMatrix, MediHoney) and realization of transformation savings.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 29, 2026 | $0.56 est $0.48 | $418.8M est $417.5M | −13.4% |
| May 5, 2026 | $0.54 est $0.40 | $391.9M est $381.8M | +31.5% |
| Feb 26, 2026 | $0.83 est $0.79 | $434.9M est $429.6M | −1.8% |
| Oct 30, 2025 | $0.54 est $0.43 | $402.1M est $429.6M | −22.2% |
| Jul 31, 2025 | $0.45 est $0.43 | $415.6M est $414.3M | −0.5% |
| May 5, 2025 | $0.41 est $0.43 | $382.7M est $402.6M | −24.3% |
| Feb 25, 2025 | $0.97 est $0.86 | $442.6M est $411.7M | +7.0% |
| Nov 4, 2024 | $0.41 est $0.39 | $380.8M est $445.5M | +29.2% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Integra LifeSciences stock forecast and analyst price targets
Analysts’ average 12-month price target for Integra LifeSciences is $18.38, +31.5% from the last close, from 7 firms rating the stock in the last 90 days.
$18.38consensus 12-month target, +31.5% from the last close
Now $13.98Avg $18.38
Low $15High $19
Each firm’s latest rating in the last 90 days: 7 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 5 | Citi | $15 | +7.3% |
| Oct 5 | Truist Financial | — | — |
| Oct 2 | BMO Capital | $15 | +7.3% |
| Oct 2 | Wells Fargo | $15 | +7.3% |
| Oct 2 | BTIG | — | — |
−3.0%average 20-day move after past Accumulation readings
+12.2%average move over the next 20 trading days in the last 5 years
±6%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Integra LifeSciences seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Integra LifeSciences averaged +12.2% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +5.6% | 5 of 5 |
| Next 10 trading days | +6.1% | 4 of 5 |
| Next 15 trading days | +2.0% | 3 of 5 |
| Next 20 trading days | +12.2% | 3 of 5 |
| Next 30 trading days | +8.4% | 4 of 5 |
For scale, IART’s typical 20-trading-day move in either direction is about 8%.
Integra LifeSciences market cap and key statistics
Integra LifeSciences’s market cap is $1.09B and revenue of $1.65B over the last twelve months.
Valuation
- Market cap
- $1.09B
- Forward P/E
- 6
- EPS, TTM
- −$0.09
- Gekko Fair Value
- $18.58
Trading
- Volume
- 893,706
- Avg volume, 20 days
- 1.16M
- 52-week high
- $20.49
- 52-week low
- $8.70
- Shares outstanding
- 77.77M
Financials
- Revenue, TTM
- $1.65B
- Profit margin
- -0.4%
- Return on equity
- -0.7%
- Quarterly earnings growth, YoY
- +0.4%
Risk and income
- Beta
- 1.21
- Typical daily move
- ±6%
- Typical 20-day move
- ±8%
Integra LifeSciences stock news this week
Coverage of Integra LifeSciences this week reads negative: 0 positive, 3 neutral and 3 negative headlines.
- Integra LifeSciences (NASDAQ:IART) & Precision Optics (NASDAQ:POCI) Critical ReviewDefense World, Oct 12
- Integra LifeSciences (NASDAQ: IART) prices $450 million notes to refinance debtDefense World, Oct 12
- Integra prices $450M 9.50% senior secured notes due 2033 to refinance debtTradingView, Oct 9
- Integra LifeSciences Holdings (IART) Cuts 2026 Revenue Outlook, Is The Stock Below Fair Value?Yahoo Finance, Oct 9
- A Look at Integra Lifesciences Holdings Corp (IART) After 3.1% Gain -- GF Value $20.47 vs Price $13.41GuruFocus, Oct 8
- INTEGRA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Integra LifeSciences Holdings Corporation on Behalf of Integra Stockholders and Encourages Investors to Contact the FirmGlobeNewsWire, Oct 6
Integra LifeSciences peers
Integra LifeSciences’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 18.2% above |
| ABTAbbott Laboratories | Neutral | 14.7% below |
| DHRDanaher | Neutral | 4.5% above |
| ISRGIntuitive Surgical | Neutral | 18.8% above |
| MDTMedtronic | Neutral | 22.9% below |
| SYKStryker | Accumulation | 12.6% below |
A peer links to its own page where one exists.
Integra LifeSciences stock FAQ
What is Integra LifeSciences’s market cap?
Integra LifeSciences’s market cap is $1.09B at the Oct 12, 2026 close of $13.98, with 77.77M shares outstanding.
What is the Integra LifeSciences stock forecast?
The consensus analyst 12-month price target for Integra LifeSciences is $18.38, +31.5% from the last close. Of the 7 firms that rated the stock in the last 90 days, 0 rate it a buy, 6 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.
Is Integra LifeSciences stock overvalued or undervalued?
On Gekko’s estimate Integra LifeSciences is undervalued: the Oct 12, 2026 close of $13.98 is 24.8% below Gekko Fair Value of $18.58. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Integra LifeSciences report earnings next?
Integra LifeSciences is expected to report on Oct 21, 2026, before the market opens (9 days away). Analysts expect earnings of $0.56 per share on revenue of $415.4M. Integra LifeSciences beat the earnings estimate in 7 of its last 8 reports, moving 16.2% on average across the report.
What is Integra LifeSciences’s 52-week high and low?
Integra LifeSciences’s 52-week high is $20.49 and its 52-week low is $8.70; it closed at $13.98 on Oct 12, 2026, −1.3% over the past year. Over the last five years the shares peaked at $74.98 on Nov 2, 2021.
Is Integra LifeSciences stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and seasonality), 1 as mixed (trend) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Integra LifeSciences the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.